Publicado 6 números por año
ISSN Imprimir: 1045-4403
ISSN En Línea: 2162-6502
Indexed in
Functional Implications of BRCA1 for Early Detection, Prevention, and Treatment of Breast Cancer
SINOPSIS
The tumor suppressor gene BRCA1 was positionally cloned in 1994. During the last 12 years, several lines of evidence have implicated BRCA1 in the maintenance of genome integrity, regulation of transcriptionn, and chromatin remodeling, suggesting that it has multiple biological roles. Germline mutations in BRCA1 confer a 56%−80% lifetime risk for breast cancer and a 15%−60% lifetime risk for ovarian cancer in women. And preliminary evidence suggests that BRCA1-linked breast and ovarian tumors behave differently from sporadic tumors, justifying a tailored approach to these cancers. Although several gaps still remain in our knowledge, it is possible to use information from basic research to illuminate clinical decisions and improve the prospects of mutation carriers. Along similar lines, genetic data derived from the clinical setting are also instrumental in determining which biochemical functions of BRCA1 contribute to its tumor suppressor actions. In this article, we explore the functional implications of BRCA1 for genetic testing (early detection), prevention, and therapy.
-
Millot Gaël A., Carvalho Marcelo A., Caputo Sandrine M., Vreeswijk Maaike P.G., Brown Melissa A., Webb Michelle, Rouleau Etienne, Neuhausen Susan L., Hansen Thomas v. O., Galli Alvaro, Brandão Rita D., Blok Marinus J., Velkova Aneliya, Couch Fergus J., Monteiro Alvaro N.A., A guide for functional analysis ofBRCA1variants of uncertain significance, Human Mutation, 33, 11, 2012. Crossref
-
Ren Jie, Jin Feng, Yu Zhaojin, Zhao Lin, Wang Lin, Bai Xuefeng, Zhao Haishan, Yao Weifan, Mi Xiaoyi, Wang Enhua, Olopade Olufunmilayo I., Wei Minjie, MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency, Tumor Biology, 34, 6, 2013. Crossref
-
Carvalho Renato S, Fernandes Vanessa C, Nepomuceno Thales C, Rodrigues Deivid C, Woods Nicholas T, Suarez-Kurtz Guilherme, Chammas Roger, Monteiro Alvaro N, Carvalho Marcelo A, Characterization ofLGALS3(galectin-3) as a player in DNA damage response, Cancer Biology & Therapy, 15, 7, 2014. Crossref
-
Price Melissa, Monteiro Alvaro N.A., Fine tuning chemotherapy to match BRCA1 status, Biochemical Pharmacology, 80, 5, 2010. Crossref
-
Lai Dulcie, Visser-Grieve Stacy, Yang Xiaolong, Tumour suppressor genes in chemotherapeutic drug response, Bioscience Reports, 32, 4, 2012. Crossref